Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Targeted Nutritional Management for Children With Chronic Kidney Disease

26. august 2026 oppdatert av: Martina Tharwat Attia salama, Assiut University

Targeted Nutritional Management for Children With Chronic Kidney Disease and Its Impact on Their Health Status and Functional Capacity

To assess the effect of various nutritional interventions including the use of specific milk formulas on healthy status, growth parameters, body composition, skeletal muscle mass and functional capacity in patients with chronic kidney disease.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

The Kidney Disease Improving Global Outcomes (KDIGO) 2024 defined the chronic kidney disease as abnormalities of kidney structure or function, present for a minimum of 3 months, with implications for health. CKD is classified based on Cause, Glomerular filtration rate (GFR) category (G1-G5), and Albuminuria category (A1-A3).

Nutritional management of pediatric patients with kidney disease is challenging as they undergo continued growth and development. So providing adequate nutrition for growth while minimizing disease progression and complications is the primary challenge.

There are many reasons for poor growth in children with (CKD), One of the most important of these is inadequate nutritional intake which may be due to anorexia, which is common in CKD, gastro-esophageal reflux with recurrent vomiting. The consequences of poor nutrition in children are suboptimal growth and impaired achievement of final height potential, abnormal body composition, developmental delay, a worsening of uremic symptoms such as vomiting, protein-energy wasting, and increased mortality.

optimizing the dietary prescription for the child with CKD is of vital importance at any age to promote growth and reverse growth failure if present.

During progression of chronic kidney disease, the requirements and utilization of different nutrients change significantly. These changes ultimately place patients with kidney disease at higher risk for nutritional and metabolic abnormalities so regular assessment of nutritional status and provision of suitable nutrition are key parts in the overall management of children with CKD aiming at preventing protein-energy malnutrition, meeting the patient's micronutrients needs and preventing overnutrition and the long-term implications of an undesirable eating routine.

unbalanced dietary pattern, characterized by high animal protein content: may worsen metabolic control, accelerate renal deterioration and consequently aggravate the stage of the chronic kidney disease in pediatric patients.

CKD is associated with chronic low-grade inflammation causing catabolic destruction of structural and functional proteins, resulting in skeletal muscle wasting, leading to progressive weight loss, muscle weakness in children resulting in a decrease in functional capacity.

Patients with advanced CKD are at high risk of cardiovascular disease (CVD). Complex changes in both the cardiac and vascular systems results in structural and functional changes that can lead to reduced exercise tolerance, quality of life and ultimately premature death.

A multidisciplinary team should consistently communicate the same messages about nutrition to provide support to the family. Educational resources, whether verbal, written, pictorial, or digital, must be adapted to suit the learning style of the child and family so that they understand the need for any nutritional interventions. This understanding, in turn, will lead to better adherence and improved outcomes for the child with CKD.

Studietype

Observasjonsmessig

Registrering (Antatt)

128

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Noha M Gamal, Lecturer
  • Telefonnummer: 020 1010321034
  • E-post: nmgped@aun.edu.eg

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

School age children with CKD from 6_12 years with all stages of CKD according to KDIGO classification

Beskrivelse

Inclusion criteria:

  1. The school age children with CKD aged from 6 years up to 12 years old.
  2. All stages of CKD according to KDIGO classification -

Exclusion Criteria:

  1. patients below 6 years or over than 12 years old.
  2. patients aren't adherent to nutritional instructions.
  3. Presence of any other disease. -

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Targeted nutritional management for children with chronic kidney disease and its impact on their health status and functional capacity
Tidsramme: One year
optimizing the dietary prescription for the children with CKD to promote growth and reverse growth failure if present aiming at preventing protein-energy malnutrition, meeting the patient's micronutrients needs and preventing overnutrition and the long-term implications of an undesirable eating routine.
One year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Osama M Elasher, Professor, Assiut university Children's Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. oktober 2026

Primær fullføring (Antatt)

30. september 2027

Studiet fullført (Antatt)

28. februar 2028

Datoer for studieregistrering

Først innsendt

23. august 2026

Først innsendt som oppfylte QC-kriteriene

26. august 2026

Først lagt ut (Faktiske)

31. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

31. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere